export const referencesData = {
  "27": {
    text: "Vietti T, Eggerding F, Valeriote F. Combined effect of x radiation and 5-fluorouracil on survival of transplanted leukemic cells. J Natl Cancer Inst. 1971 Oct;47(4):865-70.",
    url: "https://pubmed.ncbi.nlm.nih.gov/5097154/"
  },
  "47": {
    text: "Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res Off J Am Assoc Cancer Res. 1999 Dec;5(12):4191-8.",
    url: "https://pubmed.ncbi.nlm.nih.gov/10632360/"
  },
  "60": {
    text: "Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Jan 1;23(1):17-23.",
    url: "https://doi.org/10.1200/jco.2005.09.048"
  },
  "61": {
    text: "Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Jan 1;23(1):24-9.",
    url: "https://doi.org/10.1200/JCO.2005.01.198"
  },
  "62": {
    text: "Harris EER, Christensen VJ, Hwang WT, Fox K, Solin LJ. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Jan 1;23(1):11-6.",
    url: "https://doi.org/10.1200/JCO.2005.09.056"
  },
  "63": {
    text: "Azria D, Gourgou S, Sozzi WJ, Zouhair A, Mirimanoff RO, Kramar A, et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer. 2004 Oct 4;91(7):1251-60.",
    url: "https://doi.org/10.1038/sj.bjc.6602146"
  },
  "64": {
    text: "Bourgier C, Castan F, Riou O, Nguyen TD, Peignaux K, Lemanski C, et al. Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial. Oncotarget. 2018 Mar 20;9(21):15757-65.",
    url: "https://doi.org/10.18632/oncotarget.24606"
  },
  "65": {
    text: "Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase Inhibitors in the Treatment of Breast Cancer. Endocr Rev. 2005 May 1;26(3):331-45.",
    url: "https://doi.org/10.1210/er.2004-0015"
  },
  "67": {
    text: "Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol. 2010 Mar 1;11(3):258-65.",
    url: "https://doi.org/10.1016/s1470-2045(10)70013-9"
  },
  "68": {
    text: "Bourgier C, Kerns S, Gourgou S, Lemanski C, Gutowski M, Fenoglietto P, et al. Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial. Ann Oncol Off J Eur Soc Med Oncol. 2016 Mar;27(3):474-80.",
    url: "https://doi.org/10.1093/annonc/mdv602"
  },
  "82": {
    text: "Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, Azambuja E de, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet Lond Engl. 2017 Feb 17;389(10075):1195.",
    url: "https://doi.org/10.1016/s0140-6736(16)32616-2"
  },
  "83": {
    text: "Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2012 Dec 15;18(24):6634-47.",
    url: "https://doi.org/10.1158/1078-0432.ccr-12-1436"
  },
  "91": {
    text: "Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, et al. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol. 2024 Feb 1;25(2):e73–83.",
    url: "https://doi.org/10.1016/S1470-2045(23)00534-X"
  },
  "115": {
    text: "Beckmann GK, Hoppe F, Pfreundner L, Flentje MP. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck. 2005 Jan;27(1):36-43.",
    url: "https://doi.org/10.1016/s0140-6736(06)69121-6"
  },
  "121": {
    text: "Perez CA, Stanley K, Rubin P, Kramer S, Brady L, Perez-Tamayo R, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer. 1980 Jun 1;45(11):2744-53.",
    url: "https://doi.org/10.1002/1097-0142(19800601)45:11%3C2744::aid-cncr2820451108%3E3.0.co;2-u"
  },
  "130": {
    text: "Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8.",
    url: "https://doi.org/10.1016/s1470-2045(09)70311-0"
  },
  "141": {
    text: "Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-68.",
    url: "https://doi.org/10.1016/s2468-1253(22)00348-x"
  },
  "155": {
    text: "Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol Off J Am Soc Clin Oncol. 1997 May;15(5):2040-9.",
    url: "https://doi.org/10.1200/jco.1997.15.5.2040"
  },
  "156": {
    text: "Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010 Mar 30;102(7):1123-8.",
    url: "https://doi.org/10.1038/sj.bjc.6605605"
  },
  "172": {
    text: "James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. N Engl J Med. 2012 Apr 19;366(16):1477-88.",
    url: "https://doi.org/10.1056/nejmoa1106106"
  },
  "174": {
    text: "Caffo O, Thompson C, De Santis M, Kragelj B, Hamstra DA, Azria D, et al. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016 Nov;121(2):193-8.",
    url: "https://doi.org/10.1016/j.radonc.2016.09.006"
  },
  "177": {
    text: "Ivaldi GB, Leonardi M, Ferrari A, Morra A, Fossa BJ, Vavassori A, et al. Concomitant Radiotherapy and Anthracycline-based Chemotherapy in Adjuvant Breast Cancer Treatment. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):S180-1.",
    url: "https://doi.org/10.1016/j.ijrobp.2008.06.744"
  },
  "195": {
    text: "Borius PY, Régis J, Carpentier A, Kalamarides M, Valery CA, Latorzeff I. Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review. Cancer Metastasis Rev. 2021 Mar;40(1):341-54.",
    url: "https://doi.org/10.1007/s10555-020-09949-9"
  },
  "197": {
    text: "Spittle MF. Methotrexate and radiation. Int J Radiat Oncol. 1978 Jan 1;4(1):103-7.",
    url: "https://doi.org/10.1016/0360-3016(78)90123-2"
  },
  "200": {
    text: "Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009 Jun;10(6):559-68.",
    url: "https://doi.org/10.1016/s1470-2045(09)70112-3"
  },
  "201": {
    text: "Kim N, Choi SH, Chang JS, Kim YT, Kim SW, Kim GM, et al. Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer. Int J Gynecol Cancer. 2020 Dec 3;ijgc.",
    url: "https://doi.org/10.1136/ijgc-2020-002031"
  },
  "202": {
    text: "Chen F, Niu J, Wang M, Zhu H, Guo Z. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy. Radiat Oncol Lond Engl. 2024 May 30;19(1):67.",
    url: "https://doi.org/10.1186/s13014-024-02458-x"
  },
  "204": {
    text: "Guimond E, Tsai CJ, Hosni A, O'Kane G, Yang J, Barry A. Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies. Adv Radiat Oncol. 2022 Jul 14;7(6):101022.",
    url: "https://doi.org/10.1016/j.adro.2022.101022"
  },
  "207": {
    text: "Antoni D, Burckel H, Noel G. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. Cancers. 2021 May 15;13(10):2394.",
    url: "https://doi.org/10.3390/cancers13102394"
  },
  "208": {
    text: "Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, et al. Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. Lung Cancer Targets Ther. 2020 Jan 14;11:13-8.",
    url: "https://doi.org/10.2147/lctt.s224991"
  },
  "216": {
    text: "Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632-46.",
    url: "https://doi.org/10.1016/j.ijrobp.2016.01.038"
  },
  "226": {
    text: "Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer Amst Neth. 2015 Mar;87(3):232-40.",
    url: "https://doi.org/10.1016/j.lungcan.2014.12.003"
  },
  "228": {
    text: "Vaugier L, Mirabel X, Martel-Lafay I, Racadot S, Carrie C, Vendrely V, et al. Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. Cancers. 2021 Jan 11;13(2):248.",
    url: "https://doi.org/10.3390/cancers13020248"
  },
  "229": {
    text: "Komaki R, Janjan NA, Ajani JA, Lynch PM, Fairweather JS, Raijman I, et al. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncol Williston Park N. 2000 Dec;14(12 Suppl 14):34-7.",
    url: "https://pubmed.ncbi.nlm.nih.gov/11200147/"
  },
  "230": {
    text: "Hedde JP, Neuhaus T, Schüller H, Metzler U, Schmidt-Wolf IGH, Kleinschmidt R, et al. A Phase I/II Trial of Topotecan and Radiation Therapy for Brain Metastases in Patients With Solid Tumors. Int J Radiat Oncol. 2007 Jul 1;68(3):839-44.",
    url: "https://doi.org/10.1016/j.ijrobp.2007.01.004"
  },
  "231": {
    text: "Graham MV, Jahanzeb M, Dresler CM, Cooper JD, Emami B, Mortimer JE. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1215-20.",
    url: "https://doi.org/10.1016/s0360-3016(96)00367-7"
  },
  "232": {
    text: "Lange OF, Scheef W, Haase KD, Heckmann M, Leyendecker R, Urban G, et al. Palliative chemo-radiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Cancer Chemother Pharmacol. 1990 Jan 1;26(1):S74-77.",
    url: "https://doi.org/10.1007/bf00685427"
  },
  "233": {
    text: "Vermund H, Kaalhus O, Winther F, Trausjø J, Thorud E, Harang R. Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: A phase III clinical trial. Int J Radiat Oncol Biol Phys. 1985 Nov 1;11(11):1877-86.",
    url: "https://doi.org/10.1016/0360-3016(85)90267-6"
  },
  "234": {
    text: "Einhorn L, Krause M, Hornback N, Furnas B. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer. 1976 May;37(5):2414-6.",
    url: "https://doi.org/10.1002/1097-0142(197605)37:5%3C2414::aid-cncr2820370533%3E3.0.co;2-j"
  },
  "235": {
    text: "Thiele B, Stein A, Schultheiß C, Paschold L, Jonas H, Goekkurt E, et al. Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial. Clin Colorectal Cancer. 2025 Mar;24(1):11-17.",
    url: "https://doi.org/10.1016/j.clcc.2024.06.003"
  },
  "236": {
    text: "Matsuoka K, Kobunai T, Nukatsuka M, Takechi T. Improved chemoradiation treatment using trifluridine in human colorectal cancer cells in vitro. Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):249-55.",
    url: "https://doi.org/10.1016/j.bbrc.2017.10.044"
  },
  "237": {
    text: "Arrieta O, Gallardo-Rincón D, Villarreal-Garza C, Michel RM, Astorga-Ramos AM, Martínez-Barrera L, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009 Jul;4(7):845-52.",
    url: "https://doi.org/10.1097/jto.0b013e3181a97e17"
  },
  "238": {
    text: "Brade A, Brierley J, Oza A, Gallinger S, Cummings B, MacLean M, et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1027-36.",
    url: "https://doi.org/10.1016/j.ijrobp.2006.10.015"
  },
  "239": {
    text: "Kim MM, Camelo-Piragua S, Schipper M, Tao Y, Normolle D, Junck L, et al. Gemcitabine Plus Radiation Therapy for High Grade Glioma: Long-term Results of a Phase I Dose-Escalation Study. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):305-11.",
    url: "https://doi.org/10.1016/j.ijrobp.2015.10.032"
  },
  "240": {
    text: "Maraveyas A, Sgouros J, Upadhyay S, Abdel-Hamid AH, Holmes M, Lind M. Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. Br J Cancer. 2005 Mar 14;92(5):815-9.",
    url: "https://doi.org/10.1038/sj.bjc.6602444"
  },
  "241": {
    text: "Huang Y juan, Wu Y long, Xie S xi, Yang J ji, Huang Y sheng, Liao R qiang. Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial. Chin Med J (Engl). 2007 Mar 20;120(6):458-62.",
    url: "https://pubmed.ncbi.nlm.nih.gov/17439736/"
  },
  "242": {
    text: "Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, Bakker DP, Sanchez Aliaga E, Haasbeek CJA, et al. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2017 Nov;135(2):307-15.",
    url: "https://doi.org/10.1007/s11060-017-2575-9"
  },
  "243": {
    text: "Iglseder S, Nowosielski M, Bsteh G, Muigg A, Heugenhauser J, Mayer E, et al. Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2022 May;198(5):475-83.",
    url: "https://doi.org/10.1007/s00066-022-01910-9"
  },
  "244": {
    text: "Botwood N, James R, Vernon C, Price P. Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2000 Aug;11(8):1023-8.",
    url: "https://doi.org/10.1023/a:1008376306429"
  },
  "245": {
    text: "Martin DS, Kligerman MM, Fugmann RA. Radiotherapy and Adjuvant Combination Chemotherapy (6-Aminonicotinamide and 6-Mercaptopurine). Cancer Res. 1958 Sep 1;18(8_Part_1):893-6.",
    url: "https://pubmed.ncbi.nlm.nih.gov/13573360/"
  },
  "246": {
    text: "Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A. Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019 Nov;25(11):2211-6.",
    url: "https://doi.org/10.1016/j.bbmt.2019.06.017"
  },
  "247": {
    text: "Nitsche M, Christiansen H, Lederer K, Griesinger F, Schmidberger H, Pradier O. Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. J Cancer Res Clin Oncol. 2012 Jul;138(7):1113-20.",
    url: "https://doi.org/10.1007/s00432-012-1185-3"
  },
  "248": {
    text: "El Cheikh J, Bidaoui G, Atoui A, Terro K, Sharrouf L, Zahreddine A, et al. Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study. Bone Marrow Transplant. 2023 Jun;58(6):667-72.",
    url: "https://doi.org/10.1038/s41409-023-01947-z"
  },
  "249": {
    text: "Cariveau MJ, Stackhouse M, Cui XL, Tiwari K, Waud W, Secrist JA, et al. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):213-20.",
    url: "https://doi.org/10.1016/j.ijrobp.2007.09.012"
  },
  "250": {
    text: "Symonds RP, Collingwood M, Kirwan J, Humber CE, Tierney JF, Green JA, et al. Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review. Cancer Treat Rev. 2004 Aug 1;30(5):405-14.",
    url: "https://doi.org/10.1016/j.ctrv.2003.12.002"
  },
  "251": {
    text: "Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW, Shingleton HM, Blessing JA. Hydroxyurea or placebo combined with radiation to treat stages iiib and iv cervical cancer confined to the pelvis. Int J Radiat Oncol. 1979 Mar 1;5(3):317-22.",
    url: "https://doi.org/10.1016/0360-3016(79)91209-4"
  },
  "252": {
    text: "Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ, et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol Off J Am Soc Clin Oncol. 1989 Jun;7(6):761-8.",
    url: "https://doi.org/10.1200/jco.1989.7.6.761"
  },
  "253": {
    text: "Iizuka J, Hashimoto Yas, Hashimoto Yai, Kondo T, Takagi T, Nozaki T, et al. Efficacy and Feasibility of Intensity-Modulated Radiation Therapy for Prostate Cancer in Renal Transplant Recipients. Transplant Proc. 2016 Apr 1;48(3):914-7.",
    url: "https://doi.org/10.1016/j.transproceed.2016.01.032"
  },
  "254": {
    text: "Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1998 Oct;16(10):3316-22.",
    url: "https://doi.org/10.1200/jco.1998.16.10.3316"
  },
  "255": {
    text: "Hetzel FW, Brown M, Kaufman N, Bicher HI. Radiation sensitivity modification by chemotherapeutic agents. Cancer Clin Trials. 1981;4(2):177-82.",
    url: "https://pubmed.ncbi.nlm.nih.gov/7249254/"
  },
  "256": {
    text: "Cailleteau A, Maingon P, Choquet S, Bourdais R, Antoni D, Lioure B, et al. Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m2) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):677-85.",
    url: "https://doi.org/10.1016/j.ijrobp.2022.09.069"
  },
  "257": {
    text: "Byar D, Kenis Y, Van Andel JG, de Jong M, Laval P, Marion L, et al. Results of a E.O.R.T.C. randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: Prognostic factors and treatment results. Eur J Cancer 1965. 1978 Sep 1;14(9):919-30.",
    url: "https://doi.org/10.1016/0014-2964(78)90018-x"
  },
  "258": {
    text: "Eckert F, Matuschek C, Mueller AC, Weinmann M, Hartmann JT, Belka C, et al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat Oncol Lond Engl. 2010 Jun 16;5:55.",
    url: "https://doi.org/10.1186/1748-717x-5-55"
  },
  "259": {
    text: "Spalek MJ, Koseła-Paterczyk H, Borkowska A, Wągrodzki M, Szumera-Ciećkiewicz A, Czarnecka AM, et al. Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. Int J Radiat Oncol. 2021 Jul 15;110(4):1053-63.",
    url: "https://doi.org/10.1016/j.ijrobp.2021.02.019"
  },
  "260": {
    text: "Nahi H, Svedmyr E, Lerner R. Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement. Eur J Haematol. 2014;92(5):454-5.",
    url: "https://doi.org/10.1111/ejh.12247"
  },
  "261": {
    text: "Pan E, Yu D, Zhao X, Neuger A, Smith P, Chinnaiyan P, et al. Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. J Neurooncol. 2014 Sep;119(2):413-20.",
    url: "https://doi.org/10.1007/s11060-014-1510-6"
  },
  "262": {
    text: "Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, et al. Essai de phase III randomisé comparant la fotémustine seule ou associée à une irradiation encéphalique dans les métastases cérébrales de mélanome†. Cancer/Radiothérapie. 2003 Feb 1;7(1):1-8.",
    url: "https://doi.org/10.1016/s1278-3218(02)00284-6"
  },
  "263": {
    text: "Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, et al. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J Neurooncol. 2015 May 1;122(3):559-66.",
    url: "https://doi.org/10.1007/s11060-015-1745-x"
  },
  "264": {
    text: "Galetta D, Gebbia V, Silvestris N, Ferraù F, Carrozza F, Cigolari S, et al. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung Cancer. 2011 Apr 1;72(1):59-63.",
    url: "https://doi.org/10.1016/j.lungcan.2010.07.013"
  },
  "265": {
    text: "Beauchesne PD, Taillandier L, Bernier V, Carnin C. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study. Cancer Chemother Pharmacol. 2009 Jun 1;64(1):171-5.",
    url: "https://doi.org/10.1007/s00280-009-0993-x"
  },
  "266": {
    text: "Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovò MG. Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):789-93.",
    url: "https://doi.org/10.1016/s0360-3016(98)00457-x"
  },
  "267": {
    text: "Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. J Clin Oncol. 2006 Sep 20;24(27):4412-7.",
    url: "https://doi.org/10.1200/jco.2006.06.9104"
  },
  "268": {
    text: "Sanfilippo R, Hindi N, Cruz Jurado J, Blay JY, Lopez-Pousa A, Italiano A, et al. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2023 May 1;9(5):656-63.",
    url: "https://doi.org/10.1001/jamaoncol.2023.0056"
  },
  "269": {
    text: "Martin-Broto J, Hindi N, Lopez-Pousa A, Peinado-Serrano J, Alvarez R, Alvarez-Gonzalez A, et al. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. JAMA Oncol. 2020 Apr 1;6(4):535-41.",
    url: "https://doi.org/10.1001/jamaoncol.2019.6584"
  },
  "270": {
    text: "Rossoff J, Jacobsohn D, Kwon S, Kletzel M, Duerst RE, Tse WT, et al. Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatr Blood Cancer. 2021;68(8):e29087.",
    url: "https://doi.org/10.1002/pbc.29087"
  },
  "271": {
    text: "Kefela A, Sahovic E, Yao JD, Sadashiv S, Rossetti J, Fazal S, et al. Fludarabine, Intravenous Busulfan, and Total Body Irradiation (FluBuTBI) Conditioning for Allogeneic Peripheral Blood Stem Cell Transplantation the Western Pennsylvania Cancer Institute Experience. Biol Blood Marrow Transplant. 2014 Feb 1;20(2):S232.",
    url: "https://doi.org/10.1016/j.bbmt.2013.12.391"
  },
  "272": {
    text: "Seddon BM, Cassoni AM, Galloway MJ, Rees JH, Whelan JS. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. Clin Oncol R Coll Radiol G B. 2005 Aug;17(5):385-90.",
    url: "https://doi.org/10.1016/j.clon.2005.03.004"
  },
  "273": {
    text: "Kennedy RD, McAleer JJ. Radiation recall dermatitis in a patient treated with dacarbazine. Clin Oncol R Coll Radiol G B. 2001;13(6):470-2.",
    url: "https://doi.org/10.1053/clon.2001.9316"
  },
  "274": {
    text: "Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52.",
    url: "https://doi.org/10.1016/j.ijrobp.2003.08.024"
  },
  "275": {
    text: "Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, et al. Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. J Clin Oncol. 2025 Jan 20;43(3):329-38.",
    url: "https://doi.org/10.1200/jco.24.00049"
  },
  "276": {
    text: "Esteyrie V, Dehais C, Martin E, Carpentier C, Uro‐Coste E, Figarella‐Branger D, et al. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH‐Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. The Oncologist. 2021 May 1;26(5):e838-46.",
    url: "https://doi.org/10.1002/onco.13701"
  },
  "277": {
    text: "Chen WC, Kim J, Kim E, Silverman P, Overmoyer B, Cooper BW, et al. A Phase II Study of Radiotherapy and Concurrent Paclitaxel Chemotherapy in Breast-Conserving Treatment for Node-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):14-20.",
    url: "https://doi.org/10.1016/j.ijrobp.2010.08.051"
  },
  "278": {
    text: "Cai G, Cao L, Kirova YM, Feng Y, Chen JY. Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer. Radiat Oncol. 2019 Jul 2;14(1):115.",
    url: "https://doi.org/10.1186/s13014-019-1320-2"
  },
  "279": {
    text: "Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Seymour MMA. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):393-7.",
    url: "https://doi.org/10.1016/s0360-3016(00)00636-2"
  },
  "280": {
    text: "Kubota T, Sakai M, Anabuki K, Takamatsu K, Mukaida K, Kobayashi K, et al. A Phase I Trial of Weekly Nab-paclitaxel Plus Carboplatin With Thoracic Radiotherapy for Non-small Cell Lung Cancer. In Vivo. 2024 Jan 1;38(1):259-63.",
    url: "https://doi.org/10.21873/invivo.13433"
  },
  "281": {
    text: "Jiang H, Li Q, Chen B, Xi M, Makelike K, Liu S, et al. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Med. 2023;12(14):15187-98.",
    url: "https://doi.org/10.1002/cam4.6205"
  },
  "282": {
    text: "Chen S, Li J, Dong A, Liu Z, Zhu M, Jin M, et al. Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study. J Hematol OncolJ Hematol Oncol. 2023 Mar 20;16(1):26.",
    url: "https://doi.org/10.1186/s13045-023-01422-8"
  },
  "283": {
    text: "Xu Z, Xu L, Ge Y, Sun H, Zhu J, Dou Q, et al. Cabazitaxel suppresses the proliferation and promotes the apoptosis and radiosensitivity of castration-resistant prostate cancer cells by inhibiting PI3K/AKT pathway. Am J Transl Res. 2022;14(1):166-81.",
    url: "https://pubmed.ncbi.nlm.nih.gov/35173836/"
  },
  "284": {
    text: "Meattini I, Desideri I, Di Cataldo V, Francolini G, De Luca Cardillo C, Scotti V, et al. Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience. Future Oncol Lond Engl. 2016 May;12(9):1117-24.",
    url: "https://doi.org/10.2217/fon-2015-0059"
  },
  "285": {
    text: "Lee S wook, Choi EK, Lee JS, Lee SD, Suh C, Kim SW, et al. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non--small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):996-1004.",
    url: "https://doi.org/10.1016/s0360-3016(03)00127-5"
  },
  "286": {
    text: "Zelefsky MJ, Kelly WK, Scher HI, Lee H, Smart T, Metz E, et al. Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate Cancer. J Clin Oncol. 2000 May 9;18(9):1936-41.",
    url: "https://doi.org/10.1200/jco.2000.18.9.1936"
  },
  "287": {
    text: "Salama MM, Ghorab EM, Al-Abyad AG, Al-Bahy KM. Concomitant weekly vincristine and radiation followed by adjuvant vincristine and carboplatin in the treatment of high risk medulloblastoma: Ain Shams University Hospital and Sohag Cancer Center study. J Egypt Natl Cancer Inst. 2006 Jun;18(2):167-74.",
    url: "https://pubmed.ncbi.nlm.nih.gov/17496943/"
  },
  "288": {
    text: "Singhal N, Mislang A, Karapetis CS, Stephens S, Borg M, Woodman RJ, et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer: an open-label phase II multicentre trial (COVeRT study). Anticancer Drugs. 2015 Nov;26(10):1083-8.",
    url: "https://doi.org/10.1159/000092062"
  },
  "289": {
    text: "Arnold CR, Lindner AK, Schachtner G, Tulchiner G, Tulchiner N, Mangesius J, et al. Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer-a valid option for cisplatin-unfit patients? Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2022 Jan;198(1):25-32.",
    url: "https://doi.org/10.1007/s00066-021-01837-7"
  },
  "290": {
    text: "Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 Jul 31;337(5):295-300.",
    url: "https://doi.org/10.1056/nejm199707313370502"
  },
  "291": {
    text: "Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010 Nov;11(11):1066-73.",
    url: "https://doi.org/10.1016/s1470-2045(10)70223-0"
  },
  "292": {
    text: "Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937-46.",
    url: "https://doi.org/10.1016/s0360-3016(00)01516-9"
  },
  "293": {
    text: "Bourdin S, Karam G, Clemain P, Bouchot O, Peuvrel P, Lacoste J, et al. Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer. J Int Med Res. 1990;18 Suppl 1:74-8.",
    url: "https://doi.org/10.1177/03000605900180s111"
  },
  "294": {
    text: "Bolla M, Reijke TM de, Tienhoven GV, Bergh ACMV den, Oddens J, Poortmans PMP, et al. Duration of Androgen Suppression in the Treatment of Prostate Cancer. N Engl J Med. 2009 Jun 11;360(24):2516-27.",
    url: "https://doi.org/10.1056/nejmoa0810095"
  },
  "295": {
    text: "Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet Lond Engl. 2024 Jun 1;403(10442):2416-25.",
    url: "https://doi.org/10.1016/s0140-6736(24)00549-x"
  },
  "296": {
    text: "Spratt DE, George DJ, Shore ND, Cookson MS, Saltzstein DR, Tutrone R, et al. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncol. 2024 May 1;10(5):594-602.",
    url: "https://doi.org/10.1001/jamaoncol.2023.7279"
  },
  "297": {
    text: "See WA, Tyrrell CJ, CASODEX Early Prostate Cancer Trialists' Group. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol. 2006 Aug;132 Suppl 1:S7-16.",
    url: "https://doi.org/10.1007/s00432-006-0132-6"
  },
  "298": {
    text: "Nguyen PL, Kollmeier M, Rathkopf DE, Hoffman KE, Zurita AJ, Spratt DE, et al. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). J Clin Oncol. 2023;41:303.",
    url: "https://doi.org/10.1200/JCO.2023.41.6_suppl.303"
  },
  "299": {
    text: "Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, et al. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial. Eur Urol Oncol. 2025 Apr;8(2):287-295.",
    url: "https://doi.org/10.1016/j.euo.2024.06.013"
  },
  "300": {
    text: "Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, et al. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol. 2023 Feb 20;41(6):1307-17.",
    url: "https://doi.org/10.1200/jco.22.01662"
  },
  "301": {
    text: "Sargos P, Bellera C, Bentahila R, Guerni M, Benziane-Ouaritini N, Teyssonneau D, et al. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. Eur Urol Oncol. 2025 Feb;8(1):73-79.",
    url: "https://doi.org/10.1016/j.euo.2024.04.023"
  },
  "302": {
    text: "Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol Off J Am Soc Clin Oncol. 2023 Dec 20;41(36):5561-8.",
    url: "https://doi.org/10.1200/jco.23.00985"
  },
  "303": {
    text: "Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The Lancet. 2022 Jan 29;399(10323):447-60.",
    url: "https://doi.org/10.1016/s0140-6736(21)02437-5"
  },
  "304": {
    text: "Wang J, Yang Q, Haffty BG, Li X, Moran MS. Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells. Biochem Biophys Res Commun. 2013 Feb 8;431(2):146-51.",
    url: "https://doi.org/10.1016/j.bbrc.2013.01.006"
  },
  "305": {
    text: "Ding J, Guo Y, Jiang X, Li K, Fu W, Cao Y. Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer. Medicine (Baltimore). 2020 Jul 24;99(30):e21344.",
    url: "https://doi.org/10.1097/MD.0000000000021344"
  },
  "306": {
    text: "Valakh V, Trombetta MG, Werts ED, Labban G, Khalid MK, Kaminsky A, et al. Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy. Am J Clin Oncol. 2011 Jun;34(3):245-8.",
    url: "https://doi.org/10.1097/coc.0b013e3181df4b62"
  },
  "307": {
    text: "Jia R, Li W, Li M, Li R, Kong D, Li S, et al. Multicenter, randomized double-blind placebo-controlled trial of definitive concurrent chemoradiotherapy plus megestrol acetate/placebo in local-advanced esophageal cancer. J Clin Oncol. 2022 Jan 5;40(4_suppl):275-275.",
    url: "https://doi.org/10.1200/JCO.2022.40.4_suppl.275"
  },
  "308": {
    text: "McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, Stevens M, et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1180-5.",
    url: "https://doi.org/10.1016/s0360-3016(01)02782-1"
  },
  "309": {
    text: "Khan SA, Gerber DE, Zhu H, Hughes RS, Mannala S, Rashdan S, et al. Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients. J Clin Oncol. 2020 May 20;38(15_suppl):e21571-e21571.",
    url: "https://doi.org/10.1200/JCO.2020.38.15_suppl.e21571"
  },
  "310": {
    text: "Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):892-8.",
    url: "https://doi.org/10.1016/j.ijrobp.2013.11.010"
  },
  "311": {
    text: "Occhipinti M, Falcone R, Onesti CE, Botticelli A, Mazzuca F, Marchetti P, et al. Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. J Thorac Dis. 2017 Nov;9(11):E985-9.",
    url: "https://doi.org/10.21037/jtd.2017.09.74"
  },
  "312": {
    text: "Dai Y, Wei Q, Schwager C, Moustafa M, Zhou C, Lipson KE, et al. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2015 Feb;114(2):173-81.",
    url: "https://doi.org/10.1016/j.radonc.2014.12.009"
  },
  "313": {
    text: "Stagno F, Vigneri P, Fabro VD, Stella S, Restuccia N, Giallongo C, et al. Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias. Acta Oncol. 2010 Jan 1;49(1):111-2.",
    url: "https://doi.org/10.3109/02841860903302913"
  },
  "314": {
    text: "Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013 Jun 1;19(11):3050-8.",
    url: "https://doi.org/10.1158/1078-0432.ccr-13-0306"
  },
  "315": {
    text: "Joensuu H, Eriksson M, Collan J, Balk MH, Leyvraz S, Montemurro M. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2015 Aug;116(2):233-8.",
    url: "https://doi.org/10.1016/j.radonc.2015.07.025"
  },
  "316": {
    text: "Cote GM, Barysauskas CM, DeLaney TF, Schwab J, Raskin K, Lozano-Calderon S, et al. A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma. Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1496-504.",
    url: "https://doi.org/10.1016/j.ijrobp.2018.07.2013"
  },
  "317": {
    text: "Battilotti C, Proietti I, Svara F, Rizzuto G, Tolino E, Bernardini N, et al. Safe Integration of Encorafenib plus Binimetinib with Stereotactic Radiosurgery for Melanoma Brain Metastases: a Case Report. Clin Ter. 2024;175(6):374-7.",
    url: "https://doi.org/10.7417/ct.2024.5141"
  },
  "318": {
    text: "Peuvrel L, Ruellan AL, Thillays F, Quereux G, Brocard A, Saint-Jean M, et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol EJD. 2013;23(6):879-81.",
    url: "https://doi.org/10.1684/ejd.2013.2193"
  },
  "319": {
    text: "Kosydar SR, Parikh SA, Lester S, Rabe KG, Ding W, Kenderian S, et al. Safety of concurrent use of radiotherapy for second primary malignancy (SPM) in patients with chronic lymphocytic leukemia (CLL) receiving novel agent therapy. J Clin Oncol. 2023 Jun;41(16_suppl):e19507-e19507.",
    url: "https://doi.org/10.1200/JCO.2023.41.16_suppl.e19507"
  },
  "320": {
    text: "Tan B, Huang Y, Zhang B, Lin N. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway. Biomed Pharmacother Biomedecine Pharmacother. 2020 Aug;128:110133.",
    url: "https://pubmed.ncbi.nlm.nih.gov/32447207/"
  },
  "321": {
    text: "Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. Lancet Oncol 2023 Feb 1 24(2):175–86",
    url: "https://doi.org/10.1016/s1470-2045(22)00763-x"
  },
  "322": {
    text: "De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L, et al. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiat Oncol. 2017 Sep 22;12(1):157.",
    url: "https://doi.org/10.1186/s13014-017-0893-x"
  },
  "323": {
    text: "Eze C, Hegemann NS, Roengvoraphoj O, Dantes M, Manapov F. Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature. Front Oncol. 2017;7:88.",
    url: "https://doi.org/10.3389/fonc.2017.00088"
  },
  "326": {
    text: "Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, et al. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non--Small-Cell Lung Cancer. J Thorac Oncol. 2012 Dec 1;7(12):1807-14.",
    url: "https://doi.org/10.1097/jto.0b013e3182745948"
  },
  "327": {
    text: "Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2023 Jun 8;115(6):742-8.",
    url: "https://doi.org/10.1093/jnci/djac015"
  },
  "328": {
    text: "Nepote A, Poletto S, Bertaglia V, Carnio S, Piumatti C, Lanzetta C, et al. Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review. Crit Rev Oncol Hematol. 2024 Oct 30;205:104540.",
    url: "https://doi.org/10.1016/j.critrevonc.2024.104540"
  },
  "329": {
    text: "Zhou Y, Peng L, Liang F, Chu L, Chu X, Yang X, et al. Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial. EClinicalMedicine. 2024 Sep 26;76:102853.",
    url: "https://doi.org/10.1016/j.eclinm.2024.102853"
  },
  "330": {
    text: "Khan M, Zhao Z, Arooj S, Zheng T, Liao G. Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis. Front Oncol. 2020 Nov 6;10:576926.",
    url: "https://doi.org/10.3389/fonc.2020.576926"
  },
  "331": {
    text: "Khatri VM, Mills MN, Oliver DE, Yu HHM, Vogelbaum MA, Forsyth PA, et al. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases. J Neurooncol. 2023 Aug;164(1):191-7.",
    url: "https://doi.org/10.1007/s11060-023-04402-7"
  },
  "332": {
    text: "Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):597-609.",
    url: "https://doi.org/10.1056/nejmoa1914609"
  },
  "333": {
    text: "Rauf Y, Hufsey R, Robinson K, Suh JH, Chao ST, Murphy ES, et al. Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma. J Clin Oncol. 2021 May 20;39(15_suppl):2060-2060.",
    url: "https://doi.org/10.1200/JCO.2021.39.15_suppl.2060"
  },
  "334": {
    text: "Ziegler JS, Kroeze S, Hilbers ML, Imhof L, Guckenberger M, Levesque MP, et al. Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. Melanoma Res. 2020 Dec;30(6):552-61.",
    url: "https://doi.org/10.1097/cmr.0000000000000682"
  },
  "335": {
    text: "Rossi E, Schinzari G, Cellini F, Balducci M, Pasqualoni M, Maiorano BA, et al. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma. Biomedicines. 2023 Jan 29;11(2):394.",
    url: "https://doi.org/10.3390/biomedicines11020394"
  },
  "336": {
    text: "Palmer JD, Prasad RN, Fabian D, Wei L, Yildiz VO, Tan Y, et al. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2022 May;170:21-6.",
    url: "https://doi.org/10.1016/j.radonc.2022.03.016"
  },
  "337": {
    text: "Ramesh S, Cifci A, Javeri S, Minne RL, Longhurst CA, Nickel KP, et al. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1379-90.",
    url: "https://doi.org/10.1016/j.ijrobp.2023.11.013"
  },
  "338": {
    text: "Loo Gan C, Huang J, Pan E, Xie W, Schmidt AL, Labaki C, et al. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2023 Apr;6(2):204-11.",
    url: "https://doi.org/10.1016/j.euo.2022.10.004"
  },
  "339": {
    text: "Miljanic M, Vujovic D, Song T, Adams C, Tucakovic A, Goswami A, et al. Delayed Radiation Recall in Patients Receiving Cabozantinib: A Case Report and Review of the Literature. Adv Radiat Oncol. 2024 Jul 18;9(9):101576.",
    url: "https://doi.org/10.1016/j.adro.2024.101576"
  },
  "340": {
    text: "Rizzo M, Porta C. Concurrent Stereotactic Ablative Radiotherapy and Antiangiogenic Targeted Agents: Redefining the Therapeutic Strategy. Eur Urol Oncol. 2023 Apr 1;6(2):212-3.",
    url: "https://doi.org/10.1016/j.euo.2022.11.001"
  },
  "342": {
    text: "Olsen MR, Denu RA, Lyon JB, Gulliver JM, Capitini CM, DeSantes KB. Undifferentiated and Unresectable Sarcoma With NTRK3-Fusion in a Pediatric Patient Treated With Larotrectinib and Proton Beam Radiotherapy. J Pediatr Hematol Oncol. 2022 Apr 1;44(3):e770-4.",
    url: "https://doi.org/10.1097/mph.0000000000002358"
  },
  "343": {
    text: "Yang KL, Chi MS, Ko HL, Huang YY, Huang SC, Lin YM, et al. Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Radiat Oncol Lond Engl. 2021 Jan 20;16:18.",
    url: "https://doi.org/10.1186/s13014-020-01742-w"
  },
  "344": {
    text: "Rao SS, Thompson C, Cheng J, Haimovitz-Friedman A, Powell SN, Fuks Z, et al. Axitinib sensitization of high Single Dose Radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014 Apr;111(1):88-93.",
    url: "https://doi.org/10.1016/j.radonc.2014.02.010"
  },
  "345": {
    text: "Liu R, Liu Y, Zhang Z, Gao J, Zhang X, Pan Q, et al. Phase II clinical study of the safety and efficacy of sintilimab in combination with axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell cancer. J Clin Oncol. 2024 Jun;42(16_suppl):e16511-e16511.",
    url: "https://doi.org/10.1200/JCO.2024.42.16_suppl.e16511"
  },
  "346": {
    text: "Hu K, Ma MW, Gao XS, Chen JY, Li XY, Qin SB, et al. Mid-Term Analysis of the Combination Therapy of Axitinib, Toripalimab, and Stereotactic Ablative Body Radiotherapy (SABR) in the Treatment of Recurrent Metastatic Renal Cell Carcinoma. Int J Radiat Oncol. 2024 Oct 1;120(2, Supplement):e538.",
    url: "https://doi.org/10.1016/j.ijrobp.2024.07.1192"
  },
  "347": {
    text: "Weng YS, Chiang IT, Tsai JJ, Liu YC, Hsu FT. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):719-32.",
    url: "https://doi.org/10.1016/j.ijrobp.2022.09.060"
  },
  "348": {
    text: "Ji X, Xu Z, Sun J, Li W, Duan X, Wang Q. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study. Radiat Oncol Lond Engl. 2023 Jun 12;18:101.",
    url: "https://doi.org/10.1186/s13014-023-02270-z"
  },
  "349": {
    text: "Xin L, Wang L, Zhai Y, Wang S, Tang Y, Liu Y, et al. Efficacy and safety of radiotherapy combined with regorafenib for advanced hepatocellular carcinoma: A real-world study from a single center. J Clin Oncol. 2023 Jun;41(16_suppl):e16142-e16142.",
    url: "https://doi.org/10.1200/JCO.2023.41.16_suppl.e16142"
  },
  "350": {
    text: "Tian S, Nissenblatt M, Goyal S. Regorafenib-induced transverse myelopathy after stereotactic body radiation therapy. J Gastrointest Oncol. 2014 Dec;5(6):E128-31.",
    url: "https://doi.org/10.3978/j.issn.2078-6891.2014.088"
  },
  "351": {
    text: "Morikawa A, Grkovski M, Patil S, Jhaveri KL, Tang K, Humm JL, et al. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Res Treat. 2021 Jul;188(2):415-25.",
    url: "https://doi.org/10.1007/s10549-021-06209-4"
  },
  "352": {
    text: "Staehler M, Haseke N, Nuhn P, Tüllmann C, Karl A, Siebels M, et al. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int. 2011 Sep;108(5):673-8.",
    url: "https://doi.org/10.1111/j.1464-410X.2010.09895.x"
  },
  "353": {
    text: "O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, et al. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res. 2017 Jul 15;77(14):3885-93.",
    url: "https://doi.org/10.1158/0008-5472.CAN-17-0082"
  },
  "354": {
    text: "Ceylan F, Mehdiyev M, Bilgin B, Tenekeci AK, Yalçın B, Akıncı MB, et al. Palliative Radiotherapy in Metastatic Breast Cancer Patients on CDK4/6 Inhibitors: Safety Analysis. Cancers. 2025 Jan;17(3):424.",
    url: "https://doi.org/10.3390/cancers17030424"
  },
  "355": {
    text: "Bouziane J, Loap P, Cottu P, Escalup L, Kirova Y. Concurrent Use of Radiotherapy and Ribociclib: Preliminary Results and Review of the Literature. Am J Clin Oncol. 2024 Dec;47(12):574.",
    url: "https://doi.org/10.1097/coc.0000000000001131"
  },
  "356": {
    text: "Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010 May;11(5):459-64.",
    url: "https://doi.org/10.1016/S1470-2045(10)70058-9"
  },
  "357": {
    text: "Shi W, Palmer JD, Werner-Wasik M, Andrews DW, Evans JJ, Glass J, et al. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. J Neurooncol. 2016 May;127(3):535-9.",
    url: "https://doi.org/10.1007/s11060-016-2059-3"
  },
  "358": {
    text: "Drappatz J, Mantica M. Retrospective study of ivosidenib for patients with recurrent IDH mutant gliomas. J Clin Oncol. 2024 Jun 1;42(16_suppl):2040-2040.",
    url: "https://doi.org/10.1200/JCO.2024.42.16_suppl.2040"
  },
  "359": {
    text: "Macchia G, Pezzulla D, Campitelli M, Russo D, Ronzino G, Lucci S, et al. Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study. Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):465-74.",
    url: "https://doi.org/10.1016/j.ijrobp.2024.09.010"
  },
  "360": {
    text: "Macchia G, Pezzulla D, Campitelli M, Russo D, Ronzino G, Lucci S, et al. Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study. Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):465-74.",
    url: "https://doi.org/10.1016/j.ijrobp.2024.09.010"
  },
  "361": {
    text: "Loap P, Loirat D, Berger F, Cao K, Ricci F, Jochem A, et al. Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial. Int J Cancer. 2021;149(10):1828-32.",
    url: "https://doi.org/10.1002/ijc.33737"
  },
  "362": {
    text: "Lakomy DS, Urbauer DL, Westin SN, Lin LL. Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. Clin Transl Radiat Oncol. 2019 Dec 28;21:56-61.",
    url: "https://doi.org/10.1016/j.ctro.2019.12.005"
  },
  "363": {
    text: "Lao CD, Friedman J, Tsien CI, Normolle DP, Chapman C, Cao Y, et al. Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiat Oncol Lond Engl. 2013 Aug 21;8:204.",
    url: "https://doi.org/10.1186/1748-717x-8-204"
  },
  "364": {
    text: "Kubicek GJ, Werner-Wasik M, Machtay M, Mallon G, Myers T, Ramirez M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):433-9.",
    url: "https://doi.org/10.1016/j.ijrobp.2008.08.050"
  },
  "365": {
    text: "Kubicek GJ, Axelrod RS, Machtay M, Ahn PH, Anne PR, Fogh S, et al. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1192-7.",
    url: "https://doi.org/10.1016/j.ijrobp.2011.09.023"
  },
  "366": {
    text: "Barker CA, Dufault S, Arron ST, Ho AL, Algazi AP, Dunn LA, et al. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma. J Clin Oncol. 2024 Jul;42(19):2327-35.",
    url: "https://doi.org/10.1200/jco.23.01708"
  },
  "367": {
    text: "Pollom EL, Bui TT, Chang ALS, Colevas AD, Hara WY. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma. JAMA Dermatol. 2015 Sep;151(9):998-1001.",
    url: "https://doi.org/10.1001/jamadermatol.2015.0326"
  },
  "368": {
    text: "Wang K, Patel M, Prabhu AV, Lewis GD. First reported case of concurrent sonidegib and radiotherapy for recurrent, advanced basal cell carcinoma. Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol. 2021;26(1):149-52.",
    url: "https://doi.org/10.5603/RPOR.a2021.0010"
  },
  "369": {
    text: "Day D, Prawira A, Spreafico A, Waldron J, Karithanam R, Giuliani M, et al. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Oral Oncol. 2020 Sep;108:104753.",
    url: "https://doi.org/10.1016/j.oraloncology.2020.104753"
  },
  "370": {
    text: "Gryc T, Putz F, Goerig N, Ziegler S, Fietkau R, Distel LV, et al. Idelalisib may have the potential to increase radiotherapy side effects. Radiat Oncol Lond Engl. 2017 Jun 28;12(1):109.",
    url: "https://doi.org/10.1186/s13014-017-0827-7"
  },
  "371": {
    text: "Bohli M, Jaffel H, El Fida Noubbigh G, Tbessi S, Msadek F, Kochbati L. Synergistic Effect and Tolerance of Concurrent Radiotherapy and Lenalidomide Use in Relapsing Mantle Cell Lymphoma: A Case Report. Perm J. 2020 Nov;24:1-6.",
    url: "https://doi.org/10.7812/tpp/19.156"
  },
  "372": {
    text: "Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):222-7.",
    url: "https://doi.org/10.1016/j.ijrobp.2008.03.046"
  },
  "373": {
    text: "Debbi K, Loganadane G, Roulin L, Belhadj K, Boukhobza C, Saoudi A, et al. Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe! Rep Pract Oncol Radiother. 2024;29(3):408-10.",
    url: "https://doi.org/10.5603/rpor.100780"
  },
  "374": {
    text: "Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer. 2008 Oct 15;113(8):2139-45.",
    url: "https://doi.org/10.1002/cncr.23805"
  },
  "375": {
    text: "Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Feb 20;30(6):616-22.",
    url: "https://doi.org/10.1200/jco.2011.36.9116"
  },
  "376": {
    text: "Hsu WC, Chan SC, Ting LL, Chung NN, Wang PM, Ying KS, et al. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2006 Feb;36(2):93-9.",
    url: "https://doi.org/10.1093/jjco/hyi242"
  },
  "377": {
    text: "Mouzin M, Bachaud JM, Kamar N, Gamé X, Vaessen C, Rischmann P, et al. Three-dimensional conformal radiotherapy for localized prostate cancer in kidney transplant recipients. Transplantation. 2004 Nov 27;78(10):1496-500.",
    url: "https://doi.org/10.1097/01.tp.0000137933.97259.e7"
  },
  "378": {
    text: "Maroun P, Rivin E, Dumas I, Mondini M, Brahim J, Haie-Meder C, et al. Locally advanced cervical cancer in renal transplant patients: A dilemma between control and toxicity. Brachytherapy. 2014 Jan 1;13(1):88-93.",
    url: "https://doi.org/10.1016/j.brachy.2013.11.003"
  },
  "379": {
    text: "Manyam BV, Nwizu TI, Rahe ML, Harr BA, Koyfman SA. Early and Severe Radiation Toxicity Associated with Concurrent Sirolimus in an Organ Transplant Recipient with Head and Neck Cutaneous Squamous Cell Carcinoma: A Case Report. Anticancer Res. 2015 Oct;35(10):5511-4.",
    url: "https://pubmed.ncbi.nlm.nih.gov/26408717/"
  },
  "380": {
    text: "Shinohara ET, Maity A, Jha N, Lustig RA. Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck. Head Neck. 2009;31(3):406-11.",
    url: "https://doi.org/10.1002/hed.20898"
  },
  "381": {
    text: "Akthar AS, Golden DW, Nanda R, Sharma MR, Te HS, Reddy KG, et al. Early and Severe Radiation Esophagitis Associated With Concurrent Sirolimus. J Clin Oncol. 2016 Mar 20;34(9):e73-5.",
    url: "https://doi.org/10.1200/jco.2013.50.1643"
  },
  "382": {
    text: "Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, et al. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Ann Oncol. 2015 Jun 1;26(6):1223-9.",
    url: "https://doi.org/10.1093/annonc/mdv105"
  },
  "383": {
    text: "Eren MF, Ay Eren A, Sayan M, Yücel B, Elagöz Ş, Özgüven Y, et al. The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis. Medicina (Mex). 2020 Jul 13;56(7):348.",
    url: "https://doi.org/10.3390/medicina56070348"
  },
  "384": {
    text: "Miura Y, Suyama K, Shimomura A, Miyakawa J, Kobayashi H, Uki A, et al. Radiation-Induced Esophagitis Exacerbated by Everolimus. Case Rep Oncol. 2013 Jun 15;6(2):320-4.",
    url: "https://doi.org/10.1159/000353309"
  },
  "385": {
    text: "Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, et al. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 Mar;132(1):181-8.",
    url: "https://doi.org/10.1007/s11060-016-2357-9"
  },
  "386": {
    text: "König L, Dreyling M, Dürig J, Engelhard M, Hohloch K, Viardot A, et al. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial. Trials. 2019 Aug 30;20(1):544.",
    url: "https://doi.org/10.1186/s13063-019-3614-y"
  },
  "387": {
    text: "Herfarth K, Borchmann P, Schnaidt S, Hohloch K, Budach V, Engelhard M, et al. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. HemaSphere. 2018 Nov 30;2(6):e160.",
    url: "https://doi.org/10.1097/hs9.0000000000000160"
  },
  "389": {
    text: "Merx K, Martens UM, Kripp M, Hoehler T, Geissler M, Gaiser T, et al. Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Explorative Single-Arm Phase 2 Study NEORIT. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):867-75.",
    url: "https://doi.org/10.1016/j.ijrobp.2017.06.2460"
  },
  "390": {
    text: "Aboudaram A, Loap P, Loirat D, Dhia SB, Cao K, Fourquet A, et al. Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression. Cancers. 2021 Jan;13(19):4790.",
    url: "https://doi.org/10.3390/cancers13194790"
  },
  "391": {
    text: "Yang J, Zhou MY, Yu B, Lin Q, Yao Y, Wu HL, et al. A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy. Breast Edinb Scotl. 2025 Feb;79:103879.",
    url: "https://doi.org/10.1016/j.breast.2025.103879"
  },
  "392": {
    text: "Pikis S, Mantziaris G, Protopapa M, Tos SM, Kowalchuk RO, Ross RB, et al. Stereotactic radiosurgery for brain metastases from human epidermal receptor 2 positive breast Cancer: an international, multi-center study. J Neurooncol. 2024 Oct;170(1):199-208.",
    url: "https://doi.org/10.1007/s11060-024-04775-3"
  },
  "393": {
    text: "Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, et al. Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients With Recurrent Malignant Gliomas. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24.",
    url: "https://doi.org/10.1016/j.ijrobp.2010.12.074"
  },
  "394": {
    text: "Akahane K, Shirai K, Wakatsuki M, Ogawa K, Minato K, Hamamoto K, et al. Severe esophageal stenosis in a patient with metastatic colon cancer following palliative radiotherapy, ramucirumab, and chemotherapy. Clin Case Rep. 2020;8(5):919-22.",
    url: "https://doi.org/10.1002/ccr3.2751"
  },
  "395": {
    text: "Lee YL, Hsu JF, Yang CJ. Tracheoesophageal Fistula in a Patient with Advanced Non--Small Cell Lung Cancer Who Received Chemoradiotherapy and Ramucirumab. J Thorac Oncol. 2019 Jan 1;14(1):e17-8.",
    url: "https://doi.org/10.1016/j.jtho.2018.08.2031"
  },
  "396": {
    text: "Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458-64.",
    url: "https://doi.org/10.1182/blood-2016-03-703470"
  },
  "397": {
    text: "Wu SY, Fang PQ, Wang EB, Ahmed S, Duvic M, Jain P, et al. Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Adv Radiat Oncol. 2023;8(6):101279.",
    url: "https://doi.org/10.1016/j.adro.2023.101279"
  },
  "398": {
    text: "Bouziane J, Loap P, Cao K, Allali S, Gounane Y, Loganadane G, et al. Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: A Single-center Experience and Review of the Literature. Am J Clin Oncol. 2024 Dec;47(12):580.",
    url: "https://doi.org/10.1097/coc.0000000000001135"
  },
  "399": {
    text: "Seyedin SN, Harada GK, Garemanian E, Rafizadeh D, Kaakour D, Dwabe S, et al. Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2024 Dec 1;22(6):102243.",
    url: "https://doi.org/10.1016/j.clgc.2024.102243"
  },
  "400": {
    text: "Soni YS, Lock D, Ballas LK, Hwang L, Cole S, D'Souza A, et al. Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer. Int J Radiat Oncol Biol Phys. 2024 Oct 1;120(2):S74-5.",
    url: "https://doi.org/10.1016/j.ijrobp.2024.07.129"
  },
  "401": {
    text: "Krug D, Tio J, Abaci A, Beurer B, Brügge S, Elsayad K, et al. The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy--A Retrospective Multi-Center Cohort Study. Cancers. 2024 Apr 25;16(9):1649.",
    url: "https://doi.org/10.3390/cancers16091649"
  },
  "402": {
    text: "Loap P, Chabli S, Cottu P, Kirova Y. Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer. Am J Clin Oncol. 2025 Apr 3;",
    url: "https://doi.org/10.1097/coc.0000000000001195"
  },
  "403": {
    text: "Bailly-Caillé B, Kottler D, Morello R, Lecornu M, Kao W, Meyer E, et al. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study. Cancers. 2023 Jan 13;15(2):495.",
    url: "https://doi.org/10.3390/cancers15020495"
  },
  "404": {
    text: "Parikh AR, Weekes CD, Blaszkowsky LS, Franses JW, Ting DT, Mehta A, et al. A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer. J Clin Oncol. 2022 Jan 5;40(4_suppl):564-564.",
    url: "https://doi.org/10.1200/JCO.2022.40.4_suppl.564"
  },
  "405": {
    text: "Ansari J, Farrag A, Ali A, Abdelgelil M, Murshid E, Alhamad A, et al. Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab. Mol Clin Oncol. 2021 Oct;15(4):214.",
    url: "https://doi.org/10.3892/mco.2021.2376"
  },
  "406": {
    text: "McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2021 Jan 1;39(1):30-7.",
    url: "https://doi.org/10.1200/jco.20.00290"
  },
  "407": {
    text: "Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 May 1;9(5):467-75.",
    url: "https://doi.org/10.1016/s2213-2600(20)30391-x"
  },
  "408": {
    text: "Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020 Oct;8(2):e001001.",
    url: "https://doi.org/10.1136/jitc-2020-001001"
  },
  "409": {
    text: "Monjazeb AM, Daly ME, Luxardi G, Maverakis E, Merleev AA, Marusina AI, et al. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. Nat Commun. 2023 Sep 2;14:5332.",
    url: "https://doi.org/10.1038/s41467-023-40813-w"
  },
  "410": {
    text: "Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, et al. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020 Feb;15(2):248-57.",
    url: "https://doi.org/10.1016/j.jtho.2019.10.024"
  },
  "411": {
    text: "Kwan EM, Spain L, Anton A, Gan CL, Garrett L, Chang D, et al. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. Eur Urol. 2022 Mar 1;81(3):253-62.",
    url: "https://doi.org/10.1016/j.eururo.2021.08.011"
  },
  "412": {
    text: "Kazandjian D, Dew A, Hill E, Ramirez EG, Morrison C, Mena E, et al. Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. The Oncologist. 2021 Apr;26(4):288-e541.",
    url: "https://doi.org/10.1002/onco.13712"
  },
  "413": {
    text: "Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, et al. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2023 Nov 1;9(11):1505-13.",
    url: "https://doi.org/10.1001/jamaoncol.2023.3309"
  },
  "414": {
    text: "Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, et al. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 Dec;7(12):1903-9.",
    url: "https://doi.org/10.1158/2326-6066.cir-18-0793"
  },
  "415": {
    text: "Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013 Aug;1(2):92-8.",
    url: "https://doi.org/10.1158/2326-6066.cir-13-0082"
  },
  "416": {
    text: "Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 Feb 1;23(2):279-91.",
    url: "https://doi.org/10.1016/s1470-2045(21)00658-6"
  },
  "417": {
    text: "Pakkala S, Higgins K, Chen Z, Sica G, Steuer C, Zhang C, et al. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. J Immunother Cancer. 2020 Dec;8(2):e001302.",
    url: "https://doi.org/10.1136/jitc-2020-001302"
  }
}